Hanmi Science Co (008930.KS) Azione Prezzo
Hanmi Science Co Prezzo
Il fatturato è cresciuto a un tasso composto del 6,0% annuo negli ultimi 19 anni, raggiungendo 1,36 Bio. KRW. L'utile per azione è cresciuto del 2,6% all'anno negli ultimi 19 anni. Il margine netto di Hanmi Science Co si attesta al 8,7%, in aumento rispetto al 4,5% di alcuni anni fa. Hanmi Science Co offre attualmente un rendimento da dividendo di circa il 0,62%. Il payout ratio è pari a circa il 32% degli utili.
Hanmi Science Co Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Hanmi Science Co Azione e analisi azionaria
Domande frequenti sull'azione Hanmi Science Co
The business model of Hanmi Science Co Ltd., a South Korean company, revolves around its expertise in the field of biotechnology. Hanmi Science focuses on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to researching and creating cutting-edge drugs and therapies to address various medical conditions and improve patient outcomes. With a strong emphasis on research and development, Hanmi Science aims to enhance global healthcare by delivering novel treatment options to customers worldwide.
Hanmi Science Co Ltd is primarily active in the pharmaceutical and healthcare industries.
Hanmi Science Co Ltd faces competition from various companies in the market. Some of its main competitors include CJ Healthcare Corp, SK Biopharmaceuticals Co Ltd, and Yuhan Corporation. These competitors are also prominent players in the pharmaceutical and biotechnology industry.
Hanmi Science Co Ltd is a leading company in the healthcare industry. Established in 1973, Hanmi Science Co Ltd has a rich history of over four decades. The company focuses on research, development, and manufacturing of innovative medical devices and pharmaceutical products. With a strong commitment to improving global healthcare, Hanmi Science Co Ltd has made significant contributions to the industry. They have formed strategic partnerships and collaborations with renowned companies to enhance their capabilities and expand their global presence. Hanmi Science Co Ltd's dedication to quality, innovation, and customer satisfaction has positioned them as a trusted and reliable name in the healthcare sector.
Hanmi Science Co Ltd has achieved several significant milestones in its corporate history. The company made its debut in 1973 as a small chemical trading business and has since evolved into a leading global provider of pharmaceutical and healthcare solutions. Hanmi Science Co Ltd successfully developed and launched its first original drug, LUSEDRA, in 2008, marking a major advancement in the pharmaceutical sector. Additionally, the company has established numerous strategic partnerships and collaborations with global pharmaceutical giants, enabling it to enhance its research and development capabilities. Hanmi Science Co Ltd continues to foster innovation, expand its product pipeline, and deliver breakthrough treatments to improve patient outcomes.
Hanmi Science Co Ltd is primarily present in South Korea.
Hanmi Science Co Ltd represents values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on pioneering new technologies and providing top-notch services, Hanmi Science Co Ltd aims to meet the ever-evolving needs of its clients. By prioritizing research and development, the company strives to deliver cutting-edge solutions in the fields of biotechnology and pharmaceuticals. With a commitment to ethical practices, Hanmi Science Co Ltd also emphasizes integrity and social responsibility in its operations. Through its dedication to these values and its forward-thinking approach, Hanmi Science Co Ltd continues to make significant contributions to the industry.
Convertita al tasso di cambio attuale, l’azione Hanmi Science Co quota 31,91 EUR (48.100,00 KRW).
L’azione Hanmi Science Co (008930.KS) è quotata su 1 borse, tra cui: KOSPI (Seoul) (008930.KS).
Hanmi Science Co Ltd is a leading company in the pharmaceutical industry that specializes in the research and development of innovative drugs and medical devices. The company offers a wide range of products and services divided into various business areas.
Il fatturato non può essere attualmente calcolato per Hanmi Science Co.
Il profitto per Hanmi Science Co non può essere attualmente calcolato.
Il P/E per Hanmi Science Co non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per Hanmi Science Co non può essere calcolato al momento.
Il Quality Score AlleAktien per Hanmi Science Co è 5/10.
L'ISIN di Hanmi Science Co è KR7008930000. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di Hanmi Science Co è 008930.KS. Con questo simbolo di borsa vengono negoziate le azioni Hanmi Science Co in borsa.
Azione Hanmi Science Co
Gruppo di pari di Hanmi Science Co
Hanmi Science Co Ticker
Hanmi Science Co FIGI
Altre metriche e analisi di Hanmi Science Co in Deep Dive.
La nostra analisi azionaria dell'azione Hanmi Science Co include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Hanmi Science Co. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: